Influencing Physician Prescribing: Does Clinical Data Work?
At the 2002 American Heart Association meeting last November, many cardiologists could be heard expressing frustration over how to interpret and apply clinical data in their day-to-day practices. At the same time, thought leaders involved in generating the periodic guideline recommendations designed to interpret such data could be heard complaining about the low rate of compliance with guidelines. Both are addressing the same core issue: How does data change practice patterns for the better, and how can that change be made rapidly and effectively given the time it takes to complete and analyze a data set on potential outcomes?
by Mark L. Ratner
At the 2002 American Heart Association (AHA) meeting held in Chicago last November, many cardiologists attending presentations of long-term follow-up data from clinical trials could be heard expressing frustration over...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.
As the health care industry undergoes a digital transformation, the integration of AI into Quality and Regulatory Management Systems is proving essential. The challenges for successful AI deployment emphasize the need for robust digital infrastructure, data literacy programs and privacy measures to enhance patient safety and commercial performance.
Aurion Biotech is developing a cell therapy for corneal diseases that is cheap enough to produce and can be scaled that it should reach the masses in a way that other cell therapies cannot.
The whirlwind back-and-forth on US tariffs and Robert F. Kennedy jr.’s plans to deregulate health care have become all-preoccupying, but the National Academy of Medicine was first to set out President Trump’s health administration priorities.
Mikkel Wandahl Pederson, CEO and chief scientific officer at Commit Biologics, discussed the company’s mission to harness the powerful complement system for the treatment of serious diseases.
Phenomix Science presented new data at Digestive Disease Week 2025 showing its machine learning-assisted genetic risk score can predict nausea and side effects from GLP-1 receptor agonists, aiding personalized obesity treatment.
